A new study by Monash University medicine safety experts found the use of gabapentinoids—medicines widely used to treat neuropathic pain—increased the risk of hip fractures, especially in ...

Often seen as a safer alternative to opioids for the treatment of neuropathic pain, gabapentinoid use increased eightfold between 2012 and 2018, with one in seven Australians aged 80 and older ...

Although systematic reviews have outlined the current treatment options for neuropathic pain, subsequent trials have necessitated an update of the NUMBER NEEDED TO TREAT (NNT) values presented in ...

OKYO Pharma Ltd today announced the first patient has been dosed in the Phase 2 trial of topical ocular OK-101 to treat NCP. The Phase 2 clinical trial of OK-101 is a double-masked, randomized, ...

23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat corneal neuropathic pain (NCP), an ocular ...

OK-101 is the first drug candidate to enroll patients specifically diagnosed with Neuropathic Corneal Pain (NCP) in a clinical trial The Phase 2 trial is designed as a randomized, placebo-controlled, ...

A new study by Monash University medicine safety experts found the use of gabapentinoids – medicines widely used to treat neuropathic pain – increased the risk of hip fractures, especially in ...

OK-101 is the first drug candidate to enroll patients specifically diagnosed with Neuropathic Corneal Pain (NCP) in a clinical trial The Phase 2 trial is designed as a randomized, placebo-controlled, ...

Objective: To assess the efficacy, safety and impact on quality of life of tramadol in the treatment of neuropathic pain in patients with cancer. Methods: Patients with similar characteristics ...